VGXI Supports Rapid Timeline to Clinical Testing for Coronavirus Vaccine
THE WOODLANDS, TX -- VGXI, an industry leading provider of GMP grade plasmid DNA for vaccines and gene therapies, announced it has completed manufacturing and release of a DNA vaccine to combat the
COVID-19 pandemic. VGXI was selected by Inovio Pharmaceuticals in late January to produce the vaccine under a $9 million grant to Inovio from the Coalition for Epidemic Preparedness Innovations (CEPI). Rapid mobilization of efforts across both companies enabled a record-setting timeline to release and initiation of clinical testing for the novel DNA vaccine within just 2 months from the start of production and only 3 months from public release of the virus genetic sequence. The large scale manufacturing campaign has supplied thousands of vaccine doses up to 4 times faster than traditional plasmid DNA production would support.
As of today, nearly 1,300,000 cases of COVID-19 have been identified worldwide, with about 70,000 deaths. In the US, there have been over 330,000 cases and nearly 10,000 deaths. Travel, commerce, and daily life is disrupted around the world as countries implement policies to slow the spread of the virus. In parallel with these efforts, the race to make a safe, effective vaccine widely available is essential to overcoming the current crisis.
“The dedicated team at VGXI has worked tirelessly to meet this challenge,” stated VGXI CEO Mr. Young Park. “Within a fraction of the typical manufacturing timeline, VGXI has manufactured and released a vaccine for human clinical testing. We are proud to be a part of the global effort to address the COVID-19 pandemic.”
With the Phase 1 trial beginning in the US, the vaccine developer and VGXI client for the last 13 years, Inovio Pharmaceuticals, is also coordinating simultaneous clinical trials in China and South Korea. Additional large scale manufacturing of the vaccine at the VGXI facility has already been scheduled in 2Q 2020. Mr. Rob Juba, VP of Biological Manufacturing and Clinical Supply Management at Inovio Pharmaceuticals said “We are delighted to be working with our long term manufacturing partner VGXI to expedite manufacture of our COVID-19 vaccine candidate INO-4800 and enable rapid clinical testing.”
ABOUT VGXI, INC.
As a leading provider of plasmid DNA manufacturing and development services, VGXI, Inc. has proven its ability to support urgent vaccine development timelines in response to past outbreaks such as Ebola, Zika, and other coronaviruses including Middle East Respiratory Syndrome (MERS). The company has a reputation of success in manufacturing DNA products under cGMP conditions for clinical trials in the US, EU, Asia, Canada, and Australia, and its cGMP and non-GMP products have passed rigorous reviews by several international regulatory agencies. VGXI’s ability to work with unique requirements and create custom manufacturing solutions is based on its patented manufacturing process, flexible cGMP production facility, and experienced development team. VGXI, Inc. is a wholly-owned subsidiary CDMO of GeneOne Life Science, Inc. To learn more, visit http://www.vgxii.com.